Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Claims A First With Opdivo In Neoadjuvant NSCLC

Co-Primary Endpoint Data May Support Early Approval

Executive Summary

More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.

You may also be interested in...



AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff

iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.

BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver

The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.

Bristol Highlights Growth Is Not Coming From Opdivo Alone

Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel